VIVUS, Inc operates as a specialty pharmaceutical company primarily in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body-mass index of 30 or greater (obese patients) or 27 or greater (overweight patients) in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or high cholesterol.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone650-934-5200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$65.06 million
Profitability
Miscellaneous
Employees57
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable
VIVUS (NASDAQ:VVUS) Frequently Asked Questions
What is VIVUS's stock symbol?
VIVUS trades on the NASDAQ under the ticker symbol "VVUS."
When did VIVUS's stock split? How did VIVUS's stock split work?
Shares of VIVUS reverse split on Tuesday, September 11th 2018. The 1-10 reverse split was announced on Monday, September 10th 2018. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 10th 2018. An investor that had 100 shares of VIVUS stock prior to the reverse split would have 10 shares after the split.
How were VIVUS's earnings last quarter?
VIVUS, Inc. (NASDAQ:VVUS) released its quarterly earnings results on Tuesday, August, 6th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, topping the Zacks' consensus estimate of ($1.00) by $0.44. The biopharmaceutical company had revenue of $18.39 million for the quarter, compared to the consensus estimate of $16.88 million. View VIVUS's Earnings History.
When is VIVUS's next earnings date?
Has VIVUS been receiving favorable news coverage?
Media coverage about VVUS stock has been trending negative on Tuesday, InfoTrie reports. The research firm identifies positive and negative press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. VIVUS earned a daily sentiment score of -2.3 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for VIVUS.
Who are some of VIVUS's key competitors?
Some companies that are related to VIVUS include REDHILL BIOPHAR/S (RDHL), Acasti Pharma (ACST), BioXcel Therapeutics (BTAI), Generex Biotechnology (GNBT), Aldeyra Therapeutics (ALDX), Kala Pharmaceuticals (KALA), Paratek Pharmaceuticals (PRTK), Ardelyx (ARDX), Bicycle Therapeutics (BCYC), Mersana Therapeutics (MRSN), GlycoMimetics (GLYC), IDEAYA Biosciences (IDYA), Galmed Pharmaceuticals (GLMD), Humanigen (HGEN) and Corvus Pharmaceuticals (CRVS).
What other stocks do shareholders of VIVUS own?
Who are VIVUS's key executives?
VIVUS's management team includes the folowing people:
- Mr. John P. Amos, CEO & Director (Age 52)
- Mr. Kenneth Suh, Pres (Age 43)
- Mr. Mark K. Oki, Sr. VP, CFO & Chief Accounting Officer (Age 50)
- Mr. John L. Slebir, Sr. VP of Bus. Devel., Gen. Counsel & Sec. (Age 54)
- Dr. Santosh T. Varghese, Chief Medical Officer (Age 49)
Who are VIVUS's major shareholders?
VIVUS's stock is owned by many different of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (3.76%), BlackRock Inc. (2.07%) and JPMorgan Chase & Co. (0.32%). Company insiders that own VIVUS stock include Eric W Roberts, Herm Rosenman, John P Amos, Mark K Oki and Santosh T Varghese. View Institutional Ownership Trends for VIVUS.
Which institutional investors are selling VIVUS stock?
Which institutional investors are buying VIVUS stock?
VVUS stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc.. Company insiders that have bought VIVUS stock in the last two years include Eric W Roberts, Herm Rosenman, John P Amos and Mark K Oki. View Insider Buying and Selling for VIVUS.
How do I buy shares of VIVUS?
Shares of VVUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is VIVUS's stock price today?
One share of VVUS stock can currently be purchased for approximately $3.40.
How big of a company is VIVUS?
VIVUS has a market capitalization of $36.19 million and generates $65.06 million in revenue each year. The biopharmaceutical company earns $-36,950,000.00 in net income (profit) each year or ($3.48) on an earnings per share basis. VIVUS employs 57 workers across the globe.View Additional Information About VIVUS.
What is VIVUS's official website?
How can I contact VIVUS?
VIVUS's mailing address is 900 E. HAMILTON AVENUE SUITE 550, CAMPBELL CA, 95008. The biopharmaceutical company can be reached via phone at 650-934-5200 or via email at [email protected]
MarketBeat Community Rating for VIVUS (NASDAQ VVUS)
MarketBeat's community ratings are surveys of what our community members think about VIVUS and other stocks. Vote "Outperform" if you believe VVUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VVUS will underperform the S&P 500 over the long term. You may vote once every thirty days.
